Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission
NCT ID: NCT02373813
Last Updated: 2023-01-11
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
371 participants
INTERVENTIONAL
2015-02-20
2019-12-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a multicenter, randomized withdrawal, double-blind controlled study in participants with rheumatoid arthritis on etanercept plus methotrexate therapy who are in very good disease control for 6 months prior to study entry. The study will consist of a 30-day screening period, a 24-week open label run-in period, a 48-week double-blind treatment period and a 30-day safety follow-up period.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Comparing Etanercept in Combination With Methotrexate in Subjects With Rheumatoid Arthritis
NCT00565409
Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis
NCT00913458
Study Comparing Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept
NCT00459706
Study Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA Subjects
NCT00706797
Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening
NCT01578850
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Open Label Run-In: Etanercept plus Methotrexate
Etanercept 50 mg weekly by subcutaneous injection plus oral methotrexate 10 to 25 mg weekly for 24 weeks. Participants also receive folic acid as standard of care.
etanercept pre-filled syringe subcutaneous injection
etanercept for injection in pre-filled syringes
Oral methotrexate
During the open-label run-in period, methotrexate will be provided as 2.5 mg tablets.
During the double-blind treatment period, methotrexate will be provided as 2.5 mg capsules.
Folic acid (non-investigational product)
Folic acid 5 to 7 mg per week as per investigator judgment or according to local standard of care.
Double-Blind Treatment: Methotrexate Monotherapy
Oral methotrexate 10 to 25 mg weekly plus placebo for etanercept for 48 weeks. Participants also receive folic acid as standard of care.
After randomization, a participant experiencing protocol-defined disease worsening will initiate rescue treatment with etanercept 50 mg QW plus methotrexate (10 to 25 mg).
etanercept pre-filled syringe subcutaneous injection
etanercept for injection in pre-filled syringes
Oral methotrexate
During the open-label run-in period, methotrexate will be provided as 2.5 mg tablets.
During the double-blind treatment period, methotrexate will be provided as 2.5 mg capsules.
Placebo for etanercept subcutaneous injection
etanercept placebo for injection in pre-filled syringes
Folic acid (non-investigational product)
Folic acid 5 to 7 mg per week as per investigator judgment or according to local standard of care.
Double-Blind Treatment: Etanercept Monotherapy
Etanercept 50 mg weekly by subcutaneous injection plus placebo for methotrexate for 48 weeks. Participants also receive folic acid as standard of care.
After randomization, a participant experiencing protocol-defined disease worsening will initiate rescue treatment with etanercept 50 mg QW plus methotrexate (10 to 25 mg).
etanercept pre-filled syringe subcutaneous injection
etanercept for injection in pre-filled syringes
Oral methotrexate
During the open-label run-in period, methotrexate will be provided as 2.5 mg tablets.
During the double-blind treatment period, methotrexate will be provided as 2.5 mg capsules.
Placebo for methotrexate
methotrexate placebo capsules
Folic acid (non-investigational product)
Folic acid 5 to 7 mg per week as per investigator judgment or according to local standard of care.
Double-Blind Treatment: Etanercept plus Methotrexate
Etanercept 50 mg weekly by subcutaneous injection plus oral methotrexate 10 to 25 mg weekly for 48 weeks. Participants also receive folic acid as standard of care.
After randomization, a participant experiencing protocol-defined disease worsening will continue on the assigned treatments (as rescue treatment).
etanercept pre-filled syringe subcutaneous injection
etanercept for injection in pre-filled syringes
Oral methotrexate
During the open-label run-in period, methotrexate will be provided as 2.5 mg tablets.
During the double-blind treatment period, methotrexate will be provided as 2.5 mg capsules.
Folic acid (non-investigational product)
Folic acid 5 to 7 mg per week as per investigator judgment or according to local standard of care.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
etanercept pre-filled syringe subcutaneous injection
etanercept for injection in pre-filled syringes
Oral methotrexate
During the open-label run-in period, methotrexate will be provided as 2.5 mg tablets.
During the double-blind treatment period, methotrexate will be provided as 2.5 mg capsules.
Placebo for etanercept subcutaneous injection
etanercept placebo for injection in pre-filled syringes
Placebo for methotrexate
methotrexate placebo capsules
Folic acid (non-investigational product)
Folic acid 5 to 7 mg per week as per investigator judgment or according to local standard of care.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects must be in very good rheumatoid arthritis disease control for ≥ 6 months and be in remission as defined by a Simplified Disease Activity Index ≤ 3.3 at screening and at the end of the run-in period.
* Subjects must be on etanercept 50 mg per week plus methotrexate therapy for ≥ 6 months prior to the start of the run-in period. The methotrexate dose must be 10 to 25 mg per week for ≥ 6 months prior to the start of the run-in period and the dose must be stable for ≥ 8 weeks prior to the start of the run-in period.
* Subject has no known history of active tuberculosis, and has a negative test for tuberculosis during screening.
* SDAI ≤ 3.3 at run-in visit 3
* Subject if female and not at least 2 years postmenopausal or history of hysterectomy, bilateral salpingectomy, or bilateral oophorectomy, has a negative urine pregnancy test at baseline (day 1).
Exclusion Criteria
* Subject has any active infection (including chronic or localized infections) for which anti-infectives were indicated within 4 weeks prior to run-in visit 1.
* Subject has known alcohol addiction or dependency or uses alcohol daily.
* Subject has one or more significant concurrent medical conditions per investigator judgment, including the following:
* poorly controlled diabetes
* chronic kidney disease stage IIIb, IV, or V
* symptomatic heart failure (New York Heart Association class II, III, or IV)
* myocardial infarction or unstable angina pectoris within the past 12 months prior to randomization
* uncontrolled hypertension
* severe chronic pulmonary disease (eg, requiring oxygen therapy)
* multiple sclerosis or any other demyelinating disease
* major chronic inflammatory disease or connective tissue disease other than rheumatoid arthritis (eg, systemic lupus erythematosus with the exception of secondary Sjögren's syndrome)
* Any clinically significant change in the Part 1 eligibility criteria during the run-in period
* SDAI \> 3.3 and ≤ 11 on two consecutive visits at least two weeks apart OR SDAI \> 3.3 and ≤ 11 on two or more separate visits OR SDAI \> 11 at any time during the run-in period
* Subject has a clinically significant laboratory abnormality during run-in period which in the opinion of the investigator poses a safety risk, will prevent the subject from completing the study, or will interfere with the interpretation of the study results during the run-in period.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Birmingham, Alabama, United States
Research Site
Birmingham, Alabama, United States
Research Site
Huntsville, Alabama, United States
Research Site
Glendale, Arizona, United States
Research Site
Mesa, Arizona, United States
Research Site
Phoenix, Arizona, United States
Research Site
Scottsdale, Arizona, United States
Research Site
Escondido, California, United States
Research Site
Fontana, California, United States
Research Site
Hemet, California, United States
Research Site
Huntington Beach, California, United States
Research Site
La Jolla, California, United States
Research Site
Murrieta, California, United States
Research Site
Orange, California, United States
Research Site
Sacramento, California, United States
Research Site
Santa Maria, California, United States
Research Site
Torrance, California, United States
Research Site
Tustin, California, United States
Research Site
Victorville, California, United States
Research Site
West Hills, California, United States
Research Site
Doral, Florida, United States
Research Site
Fort Lauderdale, Florida, United States
Research Site
Gainesville, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Orlando, Florida, United States
Research Site
Palm Harbor, Florida, United States
Research Site
Pensacola, Florida, United States
Research Site
St. Petersburg, Florida, United States
Research Site
Tampa, Florida, United States
Research Site
Lawrenceville, Georgia, United States
Research Site
Boise, Idaho, United States
Research Site
Meridian, Idaho, United States
Research Site
Blue Island, Illinois, United States
Research Site
Skokie, Illinois, United States
Research Site
Springfield, Illinois, United States
Research Site
Granger, Indiana, United States
Research Site
Baton Rouge, Louisiana, United States
Research Site
New Orleans, Louisiana, United States
Research Site
Wheaton, Maryland, United States
Research Site
Ann Arbor, Michigan, United States
Research Site
Detroit, Michigan, United States
Research Site
Grand Rapids, Michigan, United States
Research Site
Kalamazoo, Michigan, United States
Research Site
Lansing, Michigan, United States
Research Site
Lansing, Michigan, United States
Research Site
Springfield, Missouri, United States
Research Site
St Louis, Missouri, United States
Research Site
Clifton, New Jersey, United States
Research Site
Freehold, New Jersey, United States
Research Site
Newark, New Jersey, United States
Research Site
Albuquerque, New Mexico, United States
Research Site
Brooklyn, New York, United States
Research Site
Great Neck, New York, United States
Research Site
New York, New York, United States
Research Site
Charlotte, North Carolina, United States
Research Site
Greenville, North Carolina, United States
Research Site
Oklahoma City, Oklahoma, United States
Research Site
Duncansville, Pennsylvania, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
Wynnewood, Pennsylvania, United States
Research Site
Wyomissing, Pennsylvania, United States
Research Site
Charleston, South Carolina, United States
Research Site
Orangeburg, South Carolina, United States
Research Site
Jackson, Tennessee, United States
Research Site
Knoxville, Tennessee, United States
Research Site
Carrollton, Texas, United States
Research Site
Corpus Christi, Texas, United States
Research Site
Cypress, Texas, United States
Research Site
League City, Texas, United States
Research Site
Plano, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Webster, Texas, United States
Research Site
Danville, Virginia, United States
Research Site
Buenos Aires, , Argentina
Research Site
Plovdiv, , Bulgaria
Research Site
Plovdiv, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Winnipeg, Manitoba, Canada
Research Site
Sydney, Nova Scotia, Canada
Research Site
Hamilton, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Rimouski, Quebec, Canada
Research Site
Trois-Rivières, Quebec, Canada
Research Site
Prague, , Czechia
Research Site
Uherské Hradiště, , Czechia
Research Site
Bordeaux, , France
Research Site
Cahors, , France
Research Site
Montpellier, , France
Research Site
Orléans, , France
Research Site
Paris, , France
Research Site
Berlin, , Germany
Research Site
Frankfurt am Main, , Germany
Research Site
Hildesheim, , Germany
Research Site
Leipzig, , Germany
Research Site
Püttlingen, , Germany
Research Site
Athens, , Greece
Research Site
Athens, , Greece
Research Site
Athens, , Greece
Research Site
Heraklion, , Greece
Research Site
Thessaloniki, , Greece
Research Site
Thessaloniki, , Greece
Research Site
Budapest, , Hungary
Research Site
Budapest, , Hungary
Research Site
Veszprém, , Hungary
Research Site
Bari, , Italy
Research Site
Catania, , Italy
Research Site
Florence, , Italy
Research Site
Napoli, , Italy
Research Site
Reggio Emilia, , Italy
Research Site
Roma, , Italy
Research Site
Verona, , Italy
Research Site
Mexicali, Baja California Norte, Mexico
Research Site
Guadalajara, Jalisco, Mexico
Research Site
Monterrey, Nuevo León, Mexico
Research Site
Chihuahua City, , Mexico
Research Site
Bydgoszcz, , Poland
Research Site
Karwiany, , Poland
Research Site
Sopot, , Poland
Research Site
Stalowa Wola, , Poland
Research Site
Coimbra, , Portugal
Research Site
Lisbon, , Portugal
Research Site
Lisbon, , Portugal
Research Site
Ponte de Lima, , Portugal
Research Site
Panorama, Western Cape, South Africa
Research Site
Seville, Andalusia, Spain
Research Site
Bilbao, Basque Country, Spain
Research Site
Salamanca, Castille and León, Spain
Research Site
Barcelona, Catalonia, Spain
Research Site
A Coruña, Galicia, Spain
Research Site
Majadahonda, Madrid, Spain
Research Site
El Palmar, Murcia, Spain
Research Site
Valencia, Valencia, Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Curtis JR, Trivedi M, Haraoui B, Emery P, Park GS, Collier DH, Aras GA, Chung J. Defining and characterizing sustained remission in patients with rheumatoid arthritis. Clin Rheumatol. 2018 Apr;37(4):885-893. doi: 10.1007/s10067-017-3923-z. Epub 2017 Dec 9.
Curtis JR, Emery P, Karis E, Haraoui B, Bykerk V, Yen PK, Kricorian G, Chung JB. Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission. Arthritis Rheumatol. 2021 May;73(5):759-768. doi: 10.1002/art.41589. Epub 2021 Mar 24.
Curtis JR, Stolshek B, Emery P, Haraoui B, Karis E, Kricorian G, Collier DH, Yen PK, Bykerk VP. Effects of Disease-Worsening Following Withdrawal of Etanercept or Methotrexate on Patient-Reported Outcomes in Patients With Rheumatoid Arthritis: Results From the SEAM-RA Trial. J Clin Rheumatol. 2023 Jan 1;29(1):16-22. doi: 10.1097/RHU.0000000000001893. Epub 2022 Oct 22.
Curtis JR, Emery P, Kricorian G, Yen PK, Collier DH, Bykerk V, Haraoui B. Factors Associated With Maintenance of Remission Following Change From Combination Therapy to Monotherapy in Patients With Rheumatoid Arthritis. J Rheumatol. 2023 Sep;50(9):1114-1120. doi: 10.3899/jrheum.2022-1008. Epub 2023 Apr 15.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
AmgenTrials clinical trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20110186
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.